<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03831048</url>
  </required_header>
  <id_info>
    <org_study_id>OCS-CAR-03202019</org_study_id>
    <nct_id>NCT03831048</nct_id>
  </id_info>
  <brief_title>Donors After Circulatory Death Heart Trial</brief_title>
  <official_title>Clinical Trial to Evaluate the Safety and Effectiveness of The Portable Organ Care System (OCS™) Heart For Resuscitation, Preservation and Assessment of Hearts From Donors After Circulatory Death (DCD Heart Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TransMedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TransMedics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of the OCS Heart System to resuscitate, preserve and assess
      hearts donated after circulatory death for transplantation to increase the pool of donor
      hearts available for transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized and concurrent controlled, non-inferiority pivotal trial in which
      subjects who receive a DCD donor heart transplant will be compared to subjects who receive a
      standard criteria donor heart transplant (Standard of Care 1 [SOC1] and Standard of Care 2
      [SOC2] - from both randomized and concurrent control groups), adjusting for differences in
      risk factors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>6 months</time_frame>
    <description>Patient survival 6 months post-transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Utilization rate</measure>
    <time_frame>Within 24 hours post-transplant</time_frame>
    <description>The number of eligible DCD donor hearts that were instrumented on the OCS Heart System that meet the acceptance criteria for transplant divided by the total number of eligible DCD donor hearts that were instrumented on the OCS heart system</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>30 days</time_frame>
    <description>Patient and graft survival at 30 days post transplant</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>30 days or hospital discharge, if later than 30 days</time_frame>
    <description>Patient and graft survival at 30 days and initial hospital discharge, if later than 30 days</description>
  </other_outcome>
  <other_outcome>
    <measure>Severe heart primary graft dysfunction</measure>
    <time_frame>24 hours post transplant</time_frame>
    <description>Severe heart primary graft dysfunction of the left and/or right ventricle, not including rejection of cardiac tamponade</description>
  </other_outcome>
  <other_outcome>
    <measure>Post transplant Mechanical Circulatory Support (MCS)</measure>
    <time_frame>&gt;72 hours immediately post-transplant</time_frame>
    <description>Use of post-transplant mechanical circulatory support</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Heart Transplant</condition>
  <arm_group>
    <arm_group_label>DCD Heart Possible</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Heart Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCS Heart System</intervention_name>
    <description>Preserving and assessing donor after circulatory death hearts for transplant</description>
    <arm_group_label>DCD Heart Possible</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cold Storage</intervention_name>
    <description>Active comparator intervention</description>
    <arm_group_label>Standard of Care Heart Only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Donor Inclusion

          -  Maastricht Category III DCD donor, defined as expected death after the withdrawal of
             life- supportive therapy (WLST)

          -  Donor age 18-49 years old inclusive

          -  Warm ischemic time (WIT) ≤ 30 mins, with warm ischemic time defined as: Time from when
             mean systolic blood pressure (SBP) is &lt; 50 mmHg or peripheral saturation &lt; 70% to
             aortic cross-clamp and administration of cold cardioplegia in the donor.

        Donor Exclusion

          -  Previous cardiac surgery

          -  Known coronary artery disease

          -  Cardiogenic shock or myocardial infarction, or

          -  Sustained terminal ejection fraction (EF) of ≤ 50%, or

          -  Significant valve disease except for competent bicuspid aortic valve

        Recipient Inclusion

          -  Primary heart transplant candidates

          -  Age ≥ 18 years old

          -  Signed: (1) written informed consent document; (2) authorization to use and disclose
             protected health information; and (3) consent to TransMedics' use of recipients'
             United Network for Organ Sharing (UNOS)/Organ Procurement and Transplantation Network
             (OPTN) data and recipients' Interagency Registry for Mechanically Assisted Circulatory
             Support (INTERMACS) data.

        Recipient Exclusion

          -  Prior solid organ or bone marrow transplant

          -  Chronic use of hemodialysis or diagnosis of chronic renal insufficiency

          -  Multi-organ transplant

          -  Investigator unwilling to randomize to either arm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicholas Vesom</last_name>
      <phone>650-724-6921</phone>
      <email>nvesom@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Yasuhiro Shudo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynn Wilson</last_name>
      <email>lynn.m.wilson@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Arnar Geirsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katelyn Register</last_name>
      <phone>904-953-8503</phone>
      <email>register.katelyn@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Si Pham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Singleton</last_name>
      <phone>407-303-7120</phone>
      <email>christine.singleton@adventhealth.com</email>
    </contact>
    <investigator>
      <last_name>Scott Silvestry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Courtney Nicholas</last_name>
      <phone>813-844-4914</phone>
      <email>courtneynicholas@tgh.org</email>
    </contact>
    <investigator>
      <last_name>John Dunning, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rivka Elbein, RN, BSN, CCRC</last_name>
      <phone>4047124117</phone>
      <email>rselbei@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Mani Daneshmand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Cardiovascular Research Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Margiotti</last_name>
      <phone>317-338-6593</phone>
      <email>Regina.Margiotti@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Salerno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamila Drezek</last_name>
      <phone>617-724-2610</phone>
      <email>mailto:KDREZEK@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>David D'Alessandro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kari Thomas</last_name>
      <phone>612-863-7493</phone>
      <email>kari.m.thomas@allina.com</email>
    </contact>
    <investigator>
      <last_name>Karol Mudy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicholas Lemke</last_name>
      <phone>612-625-2687</phone>
      <email>ntlemke@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Shaffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magdalena Mamczur-Madry, RN, BSN, MS</last_name>
      <phone>718-920-3576</phone>
      <email>mmamczur@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nyph/Cumc</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Yuan</last_name>
      <phone>212-305-3009</phone>
      <email>my2573@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Koji Takeda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Casalinova</last_name>
      <phone>919-613-5621</phone>
      <email>sarah.casalinova@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Jacob Schroder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Slinger</last_name>
      <phone>615-875-2602</phone>
      <email>lisa.slinger@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Ashish Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaelin Grant</last_name>
      <phone>608-262-1551</phone>
      <email>grantk@surgery.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Kastelic</last_name>
      <phone>414-955-6813</phone>
      <email>skastelic@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>David Joyce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>February 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2019</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart preservation</keyword>
  <keyword>Beating heart transplant</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

